SLC16A13

Across TCGA pan-cancer cohorts, SLC16A13 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SLC16A13 data layer compared with 22 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher SLC16A13 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC16A13 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, LUAD, and KICH are the cancer types where SLC16A13 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.001	0.688	<.001	48	view →
LUAD	OS	Median	All	0.053	0.835	<.001	36	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
UCEC	DFS	Median	All	1.000	0.631	.045	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SLC16A13–STAD (OS)

Open the STAD breakdown →